Cell Signalling Pharmacology
Signals may arise inside cells in the absence of direct activation of a receptor. Also, signals elicited by activation of receptors may be either reinforced or curbed by interaction with other signalling pathways operating inside the cell. Thus, drugs acting solely on receptors are not able to modify such signals.
However, activation of receptors on the surface of cells remain the largest single group of targets for currently marketed drugs.
In the Cell Signalling Pharmacology Lab, we aim to better understand receptor- and non receptor-mediated 3’,5’-cyclic adenosine monophosphate (cAMP) signals, how these interact with concurrent Ca2+ signals, and which cellular functions are under the control of these signals.
We believe that knowledge about these intersecting signals is necessary for developing novel strategies to treat a range of diseases with an unmet need for novel pharmacology.
Research interests & more
Some forms of epilepsy are resistant to the currently available anti-epileptic drugs. We aim to understand the underlying mechanisms, and provide clues to novel drug targets.
- Alzheimer's disease is a common form of dementia for which no very effective treatments exist. We are looking into novel targets in brain energy metabolism.
- Astrocytes contain the sugar molecule glycogen. We have little knowledge of the role played by glycogen in the brain and we aim to change that.
Cells employ cAMP and calcium to transduce signals. We aim to identify and validate novel drug targets in these signalling pathways.
- We know little of the role of sAC-based cAMP signals in the context of cell metabolism. We aim to change that and evaluate sAC as a drug target.